Dr. Shou-Bai Chao is former president of Chinese Biopharmaceutical Association. He is currently Senior Vice President leading AstraZeneca’s BioVentures business unit to develop Biosimilars and BioBetters for global markets with leading biotech companies in China and other Asian countries. Prior to the current responsibility, Dr. Chao was Senior Vice President of Technical Operations and Manufacturing at Medimmune, a biological division of AstraZeneca. He was responsible for global operations of commercial and later stage clinical products (vaccines and antibodies) manufacturing and technical operations. Prior to joining Medimmune, Dr. Chao served as assistant vice president, Technical Operations and Product Supply at Wyeth Biotech. He was responsible for global technical operations for the flagship vaccine, Prevnar(R) and other Biopharmaceuticals. He brings comprehensive perspective with more than 20 years’ experience at Medimmune, Wyeth, Sanofi-Pasteur and Genentech in global vaccine and biopharmaceutical process and product development, manufacturing operations and quality assurance. Dr. Chao earned his doctorate and completed his postdoctoral fellowship in Biochemical Engineering from University of Waterloo, Canada.